The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

N Engl J Med. 2006 Oct 5;355(14):1409-12. doi: 10.1056/NEJMp068185.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / economics
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Injections
  • Macular Degeneration / drug therapy*
  • Ranibizumab

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Ranibizumab